HIMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hims & Hers Health (HIMS) is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 and an impatient entry style. The stock has some constructive support from bullish options positioning, hedge fund accumulation, insider neutrality, and recent business expansion news, but the overall technical trend is still weak and analyst sentiment is mostly cautious with repeated price target cuts. My direct view: hold off on buying aggressively now and wait for clearer trend improvement.
Current pre-market price is 25.54, slightly above the quoted 25.38 option snapshot price and near the R1 resistance at 25.469. RSI_6 is 60.028, which is neutral-to-bullish, but MACD histogram is -0.126 and still below zero, showing momentum remains weak. The moving average structure is bearish (SMA_200 > SMA_20 > SMA_5), which confirms the broader trend is not yet strong. The stock is trading above the pivot (23.792), so near-term support exists, but resistance at 25.469 and 26.505 may cap upside unless momentum improves. The short-term pattern summary suggests limited upside near-term and weakness over the next week and month.
["Hims & Hers expanded health services partnerships with eight new partners on 2026-05-29.", "The company expanded its health benefits program to include ten partners on 2026-05-28.", "Former Netflix CFO David Wells bought 48,400 shares on 2026-05-27, a positive insider-style confidence signal from an influential figure.", "Hims launched generic Semaglutide in Canada at a lower price on 2026-05-22, supporting growth and market expansion.", "Hedge funds are buying, with buying amount up 211.82% over the last quarter."]
["Recent analyst revisions have been mostly bearish or cautious, with multiple price target cuts.", "BofA cut its price target to $25 from $28 and kept Neutral on 2026-05-26, citing risks to the 2026 guide and pricing pressure.", "Jefferies cut to $24.50 and kept Hold after Q1 revenue and EBITDA missed estimates and FY26 EBITDA guidance was reduced.", "The company is in a transition away from compounded GLP-1s, which creates execution risk near term.", "Bearish moving average structure and negative MACD show the price trend is still weak.", "Short-term stock trend estimate points to weakness over the next week and month."]
The financial snapshot was unavailable due to an error, so I cannot assess exact latest-quarter figures. Based on analyst commentary, the latest quarter was mixed: revenue and adjusted EBITDA came in below expectations, and FY26 EBITDA guidance was cut. The latest reported quarter referenced by analysts was Q1, and the main takeaway is that growth is still being reshaped by the strategic move from compounded GLP-1s toward branded offerings. That transition may support longer-term positioning, but near-term profitability and execution are still under pressure.
Recent analyst sentiment has trended downward overall. BofA lowered its target from $32 to $25 across a series of cuts and stayed Neutral, Jefferies cut to $24.50 and kept Hold, Citi raised its target to $28 but stayed Neutral, JPMorgan cut to $33 but kept Overweight, while Needham and Canaccord remained bullish with Buy ratings and higher targets. Wall Street is split: the bull case is strong demand from the renewed Novo partnership, weight-loss subscriber growth, and brand expansion; the bear case is margin pressure, guide resets, pricing pressure, and execution risk during the GLP-1 transition. Overall, pros are still optimistic about growth potential, but the cautious camp has more evidence right now.
